Transcode Therapeutics, Inc. — Form SCHEDULE 13D/A
Filed August 3, 2026 · analyzed by the Ownership Agent
SCHEDULE 13D/A
— Neutral
significance 28/100
What the filing says
CK Life Sciences Intl (Holdings) Inc filed an amended Schedule 13D/A regarding its beneficial ownership in Transcode Therapeutics, Inc. on August 3, 2026. The filing provides an amendment to a previous disclosure of acquisition of beneficial ownership. No specific share count, percentage of ownership, dollar amounts, or substantive changes are detailed in the document header provided.
Why this rating
Amendment to 13D is routine disclosure; lacks concrete details on ownership %, shares, or transaction value. Material specifics unavailable to assess impact on $6.5M company.
See more from August 3, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.